Stryker Corporation $SYK Shares Bought by ABN Amro Investment Solutions

ABN Amro Investment Solutions grew its holdings in shares of Stryker Corporation (NYSE:SYK) by 41.4% during the 4th quarter, HoldingsChannel reports. The firm owned 200,180 shares of the medical technology company’s stock after buying an additional 58,564 shares during the period. Stryker comprises approximately 1.0% of ABN Amro Investment Solutions’ holdings, making the stock its 21st biggest position. ABN Amro Investment Solutions’ holdings in Stryker were worth $70,357,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. United Financial Planning Group LLC acquired a new position in shares of Stryker during the 3rd quarter valued at about $27,000. CGC Financial Services LLC acquired a new position in shares of Stryker during the 4th quarter valued at about $29,000. Strive Asset Management LLC acquired a new position in shares of Stryker during the 3rd quarter valued at about $30,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of Stryker during the 3rd quarter valued at about $34,000. Finally, Copia Wealth Management boosted its position in shares of Stryker by 181.6% during the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock valued at $40,000 after acquiring an additional 69 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Up 1.0%

Shares of NYSE:SYK opened at $320.99 on Thursday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The firm has a market capitalization of $123.06 billion, a PE ratio of 37.15, a price-to-earnings-growth ratio of 2.00 and a beta of 0.80. The firm’s 50-day moving average is $326.71 and its two-hundred day moving average is $350.36. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the company earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts predict that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is 40.74%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Robert W. Baird set a $385.00 price target on shares of Stryker in a research report on Friday, May 1st. Barclays lowered their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Piper Sandler reissued an “overweight” rating on shares of Stryker in a research report on Tuesday, January 27th. Finally, Wells Fargo & Company decreased their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $395.48.

Insider Transactions at Stryker

In other Stryker news, VP M Kathryn Fink sold 3,500 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the sale, the vice president directly owned 177 shares in the company, valued at $50,170.65. This represents a 95.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.60% of the stock is owned by company insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.